Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
20.06
+0.12 (0.60%)
At close: Apr 28, 2026, 4:00 PM EDT
20.00
-0.06 (-0.30%)
After-hours: Apr 28, 2026, 4:56 PM EDT
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 34.33, with a low estimate of 25 and a high estimate of 42. The average target predicts an increase of 71.14% from the current stock price of 20.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 5 | 7 | 7 |
| Buy | 7 | 7 | 6 | 6 | 5 | 6 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 13 | 12 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $40 → $35 | Buy | Maintains | $40 → $35 | +74.48% | Apr 22, 2026 |
| Baird | Baird | Buy Maintains $32 → $34 | Buy | Maintains | $32 → $34 | +69.49% | Apr 7, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $40 → $42 | Buy | Maintains | $40 → $42 | +109.37% | Mar 26, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $35 → $40 | Strong Buy | Maintains | $35 → $40 | +99.40% | Mar 26, 2026 |
| Stifel | Stifel | Strong Buy Maintains $34 → $41 | Strong Buy | Maintains | $34 → $41 | +104.39% | Mar 26, 2026 |
Financial Forecast
Revenue This Year
28.75M
Revenue Next Year
146.27M
from 28.75M
Increased by 408.85%
EPS This Year
-2.76
from -2.97
EPS Next Year
-2.53
from -2.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 77.4M | 375.7M | ||||||
| Avg | 28.7M | 146.3M | ||||||
| Low | 5.7M | 34.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,207.0% | ||||||
| Avg | - | 408.9% | ||||||
| Low | - | 19.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.47 | -1.48 | ||||||
| Avg | -2.76 | -2.53 | ||||||
| Low | -3.29 | -3.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.